This is a CME/CPD accredited activity.
Number of credits: 1
Description:
Most patients with differentiated thyroid cancer fall into low-risk
stages, where survival is >90%. Therefore, for these patients, initial
stratification for risk of structural disease recurrence should be the primary
determinant for therapeutic decision-making about surgery, radioiodine, and TSH
suppression.
After primary therapy, surveillance data from serum thyroglobulin testing and
ultrasound imaging can be used to guide long-term follow-up.
This is a CME-CPD accredited activity.
Number of credits: 1
Description
Thyroglobulin (Tg) measurement remains the cornerstone of modern management of differentiated thyroid cancer (DTC), with clinical decisions on treatment and follow-up based on the results of such measurements. However, Tg measurement is a highly complex process with many pitfalls and interferences, most notably from anti-thyroglobulin antibodies (TgAb).
This session will review and discuss issues concerning analytical aspects of hsTg and TgAb measurement and issues related to the clinical consequences of these measurements.
This is a CME-CPD accredited activity.
Number of credits: 1
Description:
This patient study recalls the standard treatments for Graves' Disease and addresses the potential side-effects of antithyroid drugs and the utility of long-term antithyroid drug therapy. By the end of the case, you will listen to Dr David Cooper's conclusion and takeaway messages.
This is a CME-CPD accredited activity.
Number of credits: 1
Description:
This course will give you an insight into the major changes that occur in thyroid physiology during pregnancy, treatment regulation and management, and potential adverse outcomes and risks associated with thyroid disease and its treatment during pregnancy, among other topics.
Number of credits: 1